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SUMMARY – We investigated concentrations and roles of insulin-like growth factor 1 (IGF-1) 
and its binding protein (IGF1BP-3), growth hormone (GH), insulin, and markers of insulin resis-
tance and infl ammation in acute myocardial infarction (AMI). We aimed to assess any possible asso-
ciation between serum GH/IGF-1 axis following AMI and short-term survival rates. A follow up 
study was performed in 2010. Study group consisted of 75 patients with Killip I and II class AMI. 
Th ere were 30 control subjects. Blood samples were obtained within 24 hours of admission and ana-
lyzed for the aforementioned hormones. Patients were followed-up during 6 months for new cardiac 
events.  Median GH was higher in AMI (0.96; range 0.6-2.4) than in controls (0.26; p<0.001). IGF-1 
was signifi cantly lower in AMI (123 vs. 132; p<0.05), and so was the IGF-1/GH ratio (p<0.001) and 
IGF1BP-3. Insulin was higher in study group, but without statistical signifi cance. However, we found 
signifi cant between-group diff erences in other markers of insulin resistance (HbA1c, glycemia, 
HOMA-IR) and infl ammation. Simple linear correlation showed positive correlation between GH 
and C-reactive protein. All patients with new cardiac events had IGF-1 below median and lower left 
ventricular ejection fraction. In conclusion, IGF-1 may aff ect outcome of AMI. GH resistance might 
be a result of infl ammatory/immune response and therefore it could be a useful prognostic marker.
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Introduction
Th ere is a complex interplay of insulin-like growth 
factor 1 (IGF-1), growth hormone (GH) and markers 
of insulin resistance and infl ammation in acute myo-
cardial infarction (AMI), thus making the story of 
AMI diffi  cult to understand. Whether the GH/IGF-1 
axis exerts cardioprotective eff ects remains controver-
sial and the underlying mechanism(s) for such actions 
are unclear1. Basic science reports have emphasized a 
fundamental role of IGF-1 in regulating myocardial 
structure and function through its benefi cial eff ects on 
cardiac myocyte survival, growth, calcium signaling 
and diff erentiation1,2. In short, the GH-IGF-1 axis in-
cludes the hypothalamic-pituitary axis (responsible for 
the production of GH), GH receptors (responsible for 
IGF production), IGF binding proteins (IGFBP) (re-
sponsible for IGF transport) and IGF receptors (re-
sponsible for IGF action). Growth hormone stimu-
lates the production of IGF-1 in most tissues, includ-
ing the cardiovascular system. Th e GH/IGF-1 axis 
regulates cardiac growth, stimulates myocardial con-
tractility, and infl uences the vascular system.
Studies revealed confl icting results related to IGF-
1 in AMI and heart failure2-5. Th e Framingham and 
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Rotterdam studies, population-based assessments of 
cardiovascular risks, have reported that a low serum 
IGF-1 level was associated with heart failure2,3. Th ere 
is an interesting question waiting for answer: does the 
GH/IGF-1 axis infl uence the outcome of AMI?
To address these issues, we investigated concentra-
tions of IGF-1, GH, insulin, markers of insulin resis-
tance and markers of infl ammation in AMI. We aimed 
to assess any possible association between serum GH/




A follow up clinical study was performed at the 
Department of Cardiology, Department of Intensive 
Care with Coronary Care Unit and Department of 
Cardiovascular Diseases, Tuzla University Clinical 
Center in Tuzla, during the period from January to 
December 2010. Th e study included 75 consecutive 
patients diagnosed with AMI (also analyzed for type 
and localization of AMI). Patient recruitment was 
based on the time of admission to the hospital. Inclu-
sion criteria for the study group were age <80 years, 
AMI diagnosed by the World Health Organization 
criteria and blood sampling <24 h of symptom onset. 
Exclusion criteria were Killip class III or IV, body 
mass index (BMI) >30 kg/m2, acromegaly, Cushing 
syndrome, severe thyroid dysfunction, chronic infl am-
matory diseases, pregnancy and women using estro-
gens, patients on glucocorticoid therapy, kidney failure 
(end stage) and liver dysfunction/failure.
Two patients were excluded from the study accord-
ing to exclusion criteria, so the analysis was performed 
on 73 AMI patients. Patients with AMI were fol-
lowed-up for a six-month period (short-term progno-
sis). Most patients with AMI enrolled in the study (60 
patients) were treated with primary percutaneous in-
tervention (PCI), followed by conventional therapy 
(angiotensin converting enzyme (ACE) inhibitor, beta 
blocker, clopidogrel, acetylsalicylic acid and lipid low-
ering agents), whereas 13 patients were not treated 
with PCI (they received only the aforementioned 
drugs). We analyzed mortality and readmissions due 
to rest angina pectoris or reinfarction (new cardiac 
events) during the study period and examined left ven-
tricular ejection fraction (LVEF).
Control group consisted of 30 healthy individuals 
presenting to the hospital for follow up check-ups (in 
this group, coronary disease was excluded by medical 
history, stress test, ultrasound and/or coronary angiog-
raphy). Th e study and control groups were gender- and 
age-matched. Baseline characteristics of AMI patients 
and control subjects are shown in Table 1. Five patients 
with previously diagnosed diabetes mellitus were on in-
sulin therapy (biphasic insulin). Mild hypertension 
(grade II) was diagnosed in 40% of study group patients.
Th e study was approved by the local ethics commit-
tee, and all patients gave their written informed con-
sent to participate in the study.
Methods
Blood samples were obtained and analyzed for the 
following hormones: growth hormone, IGF-1 and 
Table 1. Baseline characteristics of study and control 
groups
Study group Control group















Number of diseased 
coronary vessels 
3-vessel disease 25 (34.2%) None
2-vessel disease 23 (31.6%) None
1-vessel disease 24 (32.8%) None
Left main stenosis 1 (1.4%) None
Hypertension 30 (41.1%) None
Previously 
diagnosed diabetes 15(20.5%) None
Chol (mmol/L) 5.85±1.16  4.87±1.4
TG (mmol/L) 2.67±1.72 1.75±1.48
Smokers 28 (38.4%) 9 (30%)
Data are shown as mean ± SD or number of patients (%); Chol = 
cholesterol; NSTEMI = non ST segment elevation myocardial in-
farction; STEMI ST = ST segment elevation myocardial infarction; 
TG = triglycerides
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baseline insulin at Department of Nuclear Medicine, 
 Tuzla. Fasting concentrations of these hormones were 
determined in blood samples obtained within 24 h of 
admission (the mean pain to sampling time was 9±6 
h), in the morning (6:00 a.m.) in Intensive Care Unit 
and were measured after freezing at -20 °C, centri-
fugation and aliquoting at Department of Nuclear 
Medicine in Tuzla. Growth hormone was measured 
with IRMA125 Sandwich Immunoradiometric Assay 
(IRMA) (DiaSorin, Stillwater, USA), using automatic 
gamma counter for gamma emitters; IGF-1 and 
IGF1BP-3 were measured with radioimmunoassay 
(RIA) (DiaSorin, Stillwater, USA) method using 1470 
Automatic Gamma Counter (Wallac Wizard, Turku, 
Finland). Baseline insulin was measured using IRI125 
Immuno-Radioactive-Insulin (IRI) (DiaSorin, Still-
water, USA) on Automatic Gamma Counter (Wallac 
Wizard, Turku, Finland).
Complete blood count, enzymes of myocardial ne-
crosis (troponin I, creatine kinase, creatine kinase 
myocardial fraction), electrolyte concentrations, glu-
cose, urea, creatinine, uric acid, lipid profi le, glycolyzed 
hemoglobin (HbA1c) and liver function tests were 
carried out by the analytical unit of our Biochemistry 
Department by standard methods.
Th e homeostasis model of assessment-insulin re-
sistance (HOMA-IR) was calculated using the inter-
national formula (fasting glucose mmol/L x fasting 
insulin mU/L/22.5) on a HOMA-IR Calculator ver-
sion 2.2.
Echocardiography
Th e left ventricular ejection fraction (LVEF) was 
determined using Simpson’s method (rule) on two-
dimensional Vivid 3 ultrasound. As stated above, we 
measured LVEF in AMI at baseline and six months 
later, and we tried to fi nd out if LVEF correlated with 
IGF-1 or GH. All AMI patients were divided into 
two groups: patients whose IGF-1 was below median 
and patients whose IGF-1 was above median. We ana-
lyzed if there was a signifi cant diff erence in LVEF be-
tween these two groups. Additionally, we investigated 
Table 2. Concentrations of study parameters in study vs. control group and in PCI vs. non-PCI group









































































































Values are presented as medians with lower and upper quartiles in brackets, followed by p-value according to Mann-Whitney analysis; PCI = 
percutaneous coronary intervention; IGF-1 = insulin-like growth factor 1; IGF1BP3 = insulin-like growth hormone 1 binding protein 3; GH 
= growth hormone; HOMA-IR = index of insulin resistance; HbA1c = glycolyzed hemoglobin; CRP = C-reactive protein; ns = nonsignifi cant
Larisa Dizdarević-Hudić et al. Insulin-like growth factor 1 in myocardial infarction
348 Acta Clin Croat, Vol. 55, No. 3, 2016
mortality rate and the rate of readmissions due to rein-
farction or rest angina pectoris during 180 days and 
tried to fi nd out if IGF-1 level at admission infl uenced 
these rates.
Statistical methods
Th e SPSS v.15 software (SPSS Inc., Chicago, Illi-
nois, USA), Arcus Quick Stat and Microsoft Excel XP 
Professional were used on statistical analysis. Variables 
with asymmetric distribution were summarized as me-
dians and interquartile ranges. Normality tests (Shapiro-
Wilk) were used for all variables. On comparison of 
AMI patients and control subjects, continuous variables 
that were normally distributed were analyzed with two-
tailed t-test and unequally distributed variables were 
analyzed with Mann-Whitney U test. Categorical data 
and proportions were analyzed with the c2-test or Fish-
er exact test where appropriate. Regression and correla-
tion analysis was also employed, as well as the receiver 
operator characteristic (ROC) analysis. A value of two-
sided p<0.05 was considered signifi cant.
Results
Th e control and study groups did not diff er accord-
ing to age, gender and/or BMI. Shapiro Wilk test 
showed that variables were not normally distributed, 
so Mann-Whitney test was performed to analyze all 
study parameters except for IGF1BP-3. We found no 
statistically signifi cant diff erence between the study 
group and control group only when it came to insulin, 
although there was a strong tendency toward it. All 
other parameters evaluated showed statistically signifi -
cant between-group diff erences.
Median values with lower and upper quartile, and p 
values are shown in Table 2. Th ere were no statistically 
signifi cant diff erences in study parameters between the 
subgroups of AMI patients treated and not treated 
with PCI (Table 2).
Simple linear correlation analysis showed positive 
linear correlation between GH and C-reactive protein 
(CRP) (r=0.350255; p=0.0158) and between IGF-1 
and IGF1BP-3 (r=0.584808; p<0.0001). However, 
there was no linear correlation between GH and LVEF 
or between IGF-1 and LVEF.
Age, sex, BMI, prevalence of diabetes mellitus, hy-
perlipidemia, hypertension, smoking, obesity and Kil-
lip classifi cation were not diff erent between the pa-
tients with and without new cardiac events. Th e sub-
group of patients treated with PCI did not have better 
outcome as compared with non-PCI patients (in fact, 
all patients with new cardiac events were in the PCI 
group). All patients with new cardiac events (fatal and 
nonfatal) had IGF-1 below median (IGF-1<123, 
range 82 to 159). Seven of eight patients had the GH 
level above median and IGF-1/GH ratio below me-
dian. During follow up period, all patients with new 
Table 3. Values of study parameters in patients with new fatal and nonfatal cardiac events during follow up period
Fatal (No 1-No 3) 
and non fatal 




















IGF-1 (ng/mL) 102 120 122 17.04 45.9 100 122 120
GH (μIU/mL) 0.25 9.51 0.97 1.24 1.78 1.19 1 2
IGF1/STH 408 12.6 127 14.03 25.79 84.03 123 110
IGF1BP3 (ng/mL) 4305 3296 2367 4513 2367 1324 3787 2229
insulin (μIU/mL) 22.5 66.6 8.1 2.6 5.6 17.4 2.3 6.3
Glucose (mmol/L 12.4 9.6 5 6.8 6.2 7.6 10 8.5
HOMA-IR 12.4 28.42 1.8 0.8 1.54 7.42 1.02 2.38
CRP (mg/L) 11.9 218.8 14.9 14 11.8 9.7 78.6 24.2
Fibrinogen (g/L) 8 6.56 2.69 2.8 5.7 7 6.05 5.8
AP = angina pectoris (rest angina pectoris); CRP = C-reactive protein; GH = growth hormone; HbA1c = glycolyzed hemoglobin; HOMA-IR 
= index of insulin resistance; IGF-1 = insulin-like growth factor 1; NSTEMI = non ST segment elevation myocardial infarction; STEMI = ST 
segment elevation myocardial infarction
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cardiac events had impaired fasting glucose or diabetes 
mellitus according to the American Diabetes Associa-
tion criteria. It should be noted that all patients with 
new cardiac events were treated with PCI. Table 3 
shows study parameters in patients with new fatal and 
nonfatal cardiac events.
Figure 1 shows ROC analysis of parameters during 
follow up period in patients with and without new car-
diac events. Table 4 shows the cut-off  values of ana-
lyzed parameters with sensitivity, specifi city, positive 
and negative predictive values, and area under the 
curve (AUC).(Fig. 1, Table 4). We point out that cut-
CRP = C-reactive protein; GH = growth hormone; HbA1c = glycolyzed hemoglobin; HOMA-IR = index of 
insulin resistance; IGF-1 = insulin-like growth factor 1
Fig. 1. Receiver operating characteristic curve (ROC) analysis of study parameters during 
follow up period.
Table 4. Receiver operator characteristic (ROC) analysis of patients with and without new cardiac events during 
follow up period





IGF-1 123.04 1 0.528 0.264 0.528 0.611
GH 0.96 1 0.549 0.233 0.549 0.624
IGF1/GH 128.65 0.833 0.449 0.156 0.449 0.479
IGF1BP-3 1330 0.2 1 1 1 0.507
Insulin 17.09 0.375 0.744 0.214 0.744 0.375
CRP 8.8 1 0.489 0.198 0.489 0.585
Fibrinogen 6.57 0.667 0.789 0.2 0.789 0.61
Glucose 6.01 0.77 0.347 0.179 0.347 0.505
HOMA-IR 10.02 0.5 0.857 0.333 0.857 0.357
IGF-1 = insulin-like growth factor 1; GH = growth hormone; IGF1BP-3 = insulin-like growth factor 1 binding protein 3; CRP = C-reac-
tive protein; HOMA-IR = index of insulin resistance
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off  values of IGF-1 and GH represent medians of 
IGF-1 and GH in AMI at the same time.
Figure 2 shows LVEF values in AMI patients with 
IGF-1 below median and IGF-1 above median during 
hospitalization and after six months. Patients with IGF-
1 below median had a signifi cantly lower LVEF during 
hospitalization and after six months too (Fig. 2).
Discussion
In this study, the values of insulin resistant state 
(HOMA-IR) in the fi rst 24 hours following AMI 
were found to be higher in comparison with control 
group. Th e levels of fasting glucose concentration and 
HbA1c were also signifi cantly higher in the AMI 
group than in control group. Th ese results are similar 
to the results reported from some other recent stud-
ies4-12. A few well described mechanisms of hypergly-
cemia in AMI include insulin resistance, endothelial 
dysfunction, cortisol and cytokines. Baseline insulin 
levels showed no signifi cant diff erence between the 
study and control groups, which is also consistent with 
some other investigations, although HOMA-IR was 
higher in AMI, mostly because of higher glucose level 
(insulin was also higher, but the diff erence was not sta-
tistically signifi cant, so the fi nal product of insulin and 
glucose (HOMA-IR) showed a statistically signifi cant 
diff erence). In the aforementioned investigations, the 
authors also revealed insulin resistance without signifi -
cant increase in baseline insulin4,8. During follow up 
period, all patients with new cardiac events had at least 
impaired fasting glucose.
Previous studies have documented a decrease in 
IGF-1 levels following MI4-6. However, the role of 
GH/IGF-1 axis remains unclear1-4. In the present 
study, the level of IGF-1 was lower and the level of 
GH higher in AMI patients than in controls (p<0.05 
and p<0.001, respectively), and this fi nding is sugges-
tive of GH resistance.
Th e IGF-1 might also be a good marker of patient 
outcome in AMI in the fi rst six months. We believe 
that in the future, IGF-1 could be routinely measured 
as an outcome marker in 180 days, although new in-
vestigations need to be done to confi rm this. As men-
tioned before, three patients died and fi ve patients had 
nonfatal cardiac events during follow up, so the total 
number of patients with both fatal and nonfatal car-
diac events was eight. Th is number is small for clear 
predictive values and new researches need to be done, 
but we analyzed these patients as the topic is too inter-
esting and important. For example, Yamaguchi et al.6 
had fi ve non-survivors during follow up period and 
they performed all analyses on that small sample.
As mentioned above, age, sex, BMI, prevalence of 
diabetes mellitus, hyperlipidemia, hypertension, smok-
ing, obesity and Killip classifi cation were not diff erent 
between the patients with and without new cardiac 
events. Also, the subgroup of patients treated with PCI 
did not have better outcome than non-PCI group (in 
fact, all patients with new coronary events were in the 
PCI subgroup). All patients with fatal and nonfatal 
new cardiac events during follow up period had IGF-1 
below median (<123; we pointed out above that pa-
tients with AMI were divided into two subgroups ac-
cording to median). In other words, all cardiac mortal-
ity and other major new cardiac events were in the 
subgroup with IGF-1 below median, which is compa-
rable to some other investigations1,6 in which AMI 
patients were analyzed during a 90-day period. How-
ever, in the aforementioned study by Yamaguchi et al.6, 
median of IGF-1 at admission was slightly higher 
than in our study (131 vs. 123 ng/mL), the authors 
followed-up patients over a shorter period then we did 
(90 vs. 180 days), and they did not measure and in-
t=1.96 (p=0.028); t’=1.99 (p’=0.02)
LVEF = left ventricular ejection fraction; IGF 1 = insulin-like 
growth factor 1; Xr’ = mean value in patients at 6 months; t = t-test 
value during hospitalization; t’ = t-test at 6 months; Xr = mean 
value during initial hospitalization; Xr’ = mean value in patients at 
6 months
Fig. 2. LVEF values in acute myocardial infarction 
patients with IGF-1 below median and IGF-1 above 
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vestigate the relationship of GH, IGF-1/GH and 
IGF1BP-3. Moreover, our analyses showed that low 
IGF-1 level at admission might be a good prognostic 
marker at 180 days and not only at 90 days. We have to 
point out that we performed ROC analysis which 
showed low IGF1 (cut-off  ≤123) and high GH (cut-
off  ≥0.96) to have high sensitivity1 and AUC in pre-
dicting new cardiac events (123 and 0.96 are medians 
of IGF-1 and GH, respectively). On the contrary, 
IGF1BP-3, the main binding protein of IGF1, had 
low sensitivity but high specifi city, positive and nega-
tive predictive values1.
Th e role of the above mentioned IGF1BP-3 is 
complex and still controversial, and there are confl ict-
ing results of IGF1BP-3 concentration in AMI. How-
ever, the actual role is not understood fully. A few au-
thors found increased levels of IGF1BP-3 in AMI13,14, 
whereas others report on decreased levels of IGF1BP-3 
in AMI15,16. In addition, we found positive linear cor-
relation between IGF-1 and IGF1BP-3, as expected. 
Several additional aspects associated with the role of 
IGF-1 in AMI deserve consideration. Conti et al.4 
tried to explain the reasons for decreased level of IGF-
1 and its binding protein IGF1BP-3 in AMI. Th ey 
discuss whether the level of IGF-1 is the cause of AMI 
or IGF-1 decreases secondarily in AMI, and they 
point out that IGF-1 also decreased secondarily due to 
immune/infl ammatory response which exerted IGF-
1/GH axis and due to low IGF1BP-3. According to 
them, IGF1BP-3 could change plasma half-life of 
IGF-1 (plasma half-life of IGF-1 is 10 h; when IGF-1 
is in complex with IGF1BP-3 it could be 20 h). In 
other words, low concentration of IGF1BP-3 means 
low level of IGF-1. According to our results, IGF1BP-3 
level is not an independent predictor of new cardiac 
events in six-month period and it does not aff ect pa-
tient outcome signifi cantly but it is decreased in AMI 
and correlates with IGF-1.
All patients with new cardiac events (fatal and 
nonfatal) were stent treated, so the choice of therapy 
did not negatively interfere with the outcome of AMI. 
Seven of eight patients had the level of GH above me-
dian and IGF-1/GH ratio below median, so GH re-
sistance appears to be linked to AMI outcome too. 
What is the possible explanation for this? Th e acute 
changes in GH concentration are supposed to be linked 
to the degree of the infl ammatory reaction and stress 
provoked by the infarction. We also found strong pos-
itive linear correlation between CRP and GH, and 
similar results have also been reported elsewhere6. It is 
well known that infl ammation plays an important role 
in the pathogenesis and course of acute coronary syn-
drome. Previous studies found elevated concentrations 
of nonspecifi c markers of infl ammation (CRP, fi brino-
gen) in the fi rst 24 hours of AMI17-21. We also found 
higher levels of CRP and fi brinogen in AMI. Above 
all, we found that all patients with new cardiac events 
had elevated values of CRP. CRP has also high sensi-
tivity in predicting new cardiac events during 180-day 
period. We showed a strong positive correlation be-
tween infl ammation and IGF-1 axis. Additionally, 
there was no linear correlation between IGF-1 and 
markers of infl ammation or between GH/IGF-1 axis 
and markers of insulin resistance. Friberg et al.5 found 
similar results as we did. Unlike this, Conti et al.4 
found decreased level of GH in AMI. We hypothesize 
that larger infarctions trigger a stronger infl ammatory 
response and activate the GH/IGF-1 axis. Th is could 
explain such confl icting fi ndings of GH levels in AMI. 
It therefore may be speculated that IGF-1/GH ratio 
(index of GH resistance) might be a useful prognostic 
marker in AMI (the lower the IGF1/GH ratio, the 
poorer is the outcome of AMI). Further investigations 
need to be done to confi rm this hypothesis.
Th e group of patients with IGF-1 below median 
had a signifi cantly lower LVEF during hospitalization 
and six months later, at follow up check-up. At follow 
up, LVEF was slightly better than in the fi rst days of 
AMI in both groups but diff erence between the two 
groups was obvious. Th is fi nding is of importance be-
cause Scharin Täng et al.22 indicated an important role 
of circulating IGF-1 in preserving cardiac structure 
and function both in physiological settings and post 
myocardial infarction. Unlike Lee et al.7, we did not 
fi nd linear correlation between IGF-1 and LVEF. De-
spite this, we found a relationship between IGF-1 and 
LVEF without doubt, indicating that IGF-1 plays an 
important role in preserving cardiac function post 
myocardial infarction.
At the end, we want to point out that recently 
Bourron et al.23 measured IGF-1 in 1005 patients with 
AMI. Th ey investigated whether IGF-1 at admission 
for AMI predicted death, all-cause death, recurrent 
AMI and stroke over a 2-year follow up. Th ey con-
cluded that low IGF-1 score was associated with an 
increased risk of all-cause death, recurrent AMI and 
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stroke in AMI patients. Th eir study was larger than 
ours and they followed-up patients longer than we did. 
But they did not measure IGF1BP-3, GH and insu-
linemia (as we did in our study), and therefore they 
could not exclude the role of GH (or IGF1 BP-3/in-
sulin) in the higher risk of recurrent cardiovascular 
events observed in subjects with low IGF-1. Th e au-
thors of this large study also said that these were po-
tential limitations of their study. Our study was much 
smaller but we investigated precisely GH/IGF-1 axis 
and its link with insulinemia and infl ammation.
Our study limitations were single-center design 
and relatively small number of patients with new car-
diac events during short-term follow up period, thus 
precluding any defi nite conclusions.
Conclusions
Th e main fi ndings of our study were lower IGF-1 
and higher GH values in AMI as compared with con-
trol group. Besides low IGF-1/GH ratio, insulin resis-
tance and elevated markers of infl ammation were 
found in the fi rst 24 hours of AMI. Strong linear pos-
itive correlation between CRP and GH might be the 
key of GH resistance state. Although further investi-
gations are required, our results implicated that IGF-1 
level might aff ect prognosis of AMI.
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Sažetak
UTJEČU LI HORMON RASTA I INZULINU SLIČAN ČIMBENIK RASTA 1 
NA PROGNOZU U BOLESNIKA S AKUTNIM INFARKTOM MIOKARDA KLASE KILLIP I-II?
L. Dizdarević-Hudić, Z. Kusljugić, F. Baraković, M. Hajder i I. Hudić
Istraživali smo uloge inzulinu sličnog čimbenika rasta (IGF-1), njegovog vezujućeg proteina (IGF1BP-3), hormona rasta 
(growth hormone, GH), inzulina, biljega inzulinske rezistencije i upale u akutnom infarktu miokarda (AIM). Cilj je bio utvr-
diti utjecaj osovine IGF-1/GH na kratkoročnu prognozu AIM. U istraživanje provedeno tijekom 2010. godine bilo je uklju-
čeno 75 bolesnika s dijagnozom AIM (ispitna skupina) i 30 ispitanika kao kontrolna skupina. Uzorci krvi su uzimani unutar 
24 h od prijma i potom analizirani na navedene hormone. Tijekom šestomjesečnog razdoblja pratili smo hoće li doći do 
pojave novih srčanih događaja; ultrazvučno se određivala ejekcijska frakcija (EF). Medijan GH bio je veći u skupini s AIM 
nego u kontrolnoj skupini (0,96 prema 0,26; p<0,001); medijan IGF-1 bio je znatno manji u ispitnoj skupini (123 prema 132; 
p<0,05), baš kao i omjer IGF-1/GH (p<0,001) i IGF-1BP-3. Inzulin je bio viši u ispitnoj skupini, ali razlika nije bila stati-
stički značajna. Utvrđena je statistički značajna razlika u drugim glikemijskim parametrima (glukoza, HbA1c, HOMA IR) 
i nespecifi čnim biljezima upale. Utvrdili smo pozitivnu linearnu korelaciju između GH i C-reaktivnog proteina. Svi bolesni-
ci s novim koronarnim događajima imali su IGF-1 ispod medijana, te nižu EF. U zaključku, IGF-1 bi mogao utjecati na 
prognozu bolesnika s AIM. Rezistencija na GH je rezultat upalnog/imunog odgovora i mogla bi biti koristan prognostički 
biljeg.
Ključne riječi: Srčani infarkt; Akutna bolest; Inzulinu sličan faktor rasta I; Inzulinu sličan faktor rasta, vezani protein 3; 
 Hormon rasta; Inzulin; Biomarkeri; Prognoza
